Revance Therapeutics (RVNC) Tops Q3 EPS by 5c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.10), $0.05 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $20.29 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand
• UBS says bull market has further to run